DGAP-News

CureVac : CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV - Seite 3

About CVnCoV
CureVac first began development of its mRNA-based COVID-19 vaccine candidate in January 2020. The compound is based on optimized, non-chemically modified mRNA, encoding the prefusion-stabilized full spike protein of the SARS-CoV-2 virus. Formulation of CVnCoV is based on state-of-the-art lipid nanoparticle (LNP) technology licensed from the company's partner, Acuitas. The company began a Phase 1 clinical study of CVnCoV in June 2020 at clinical study centers in Germany and Belgium in collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI). At the end of September 2020 the vaccine candidate entered a Phase 2a clinical trial in Peru and Panama, further extending clinical studies into older adults and regions with high incidence of COVID-19 infections. The company plans to initiate a pivotal Phase 2b/3 clinical study by the end of 2020. Clinical trial material is provided by the company's substantial production capacities for mRNA vaccines at its headquarters in Tübingen. CureVac is currently expanding those manufacturing capacities to allow for broad-scale manufacturing of CVnCoV for potential commercial supply preparedness.

About CureVac
CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with more than 20 years of expertise in developing and optimizing this versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, the company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen Germany, and employs approximately 500 people at its sites in Tübingen, Frankfurt and Boston, USA. Further information can be found at www.curevac.com.